Company Overview and News

 
What’s Expected for Phillips 66’s 1Q18 Results

2018-04-18 marketrealist
Phillips 66 (PSX) is anticipated to post its 1Q18 results on April 27, 2018. Before we proceed with its 1Q18 estimates, let’s review its 4Q17 performance.
Upvote Downvote

 
Where Phillips 66’s Moving Averages Stand

2018-04-18 marketrealist
In 2Q17, Phillips 66 (PSX) rose, likely due to its 1Q17 numbers. However, PSX’s 50-DMA (day moving average) stood below its 200-DMA. In 3Q17, at the end of August, the refining environment strengthened due to Hurricane Harvey, and Phillips 66’s 50-DMA crossed over its 200-DMA. A short-term moving average crossing above a long-term moving average is considered a bullish technical sign.
Upvote Downvote

 
How Phillips 66’s Short Interest Compares

2018-04-18 marketrealist
Short interest in Phillips 66 (PSX) as a percentage of outstanding shares has fallen 0.3% since February 14, 2018, to 1.2%. Normally, everything else being equal, a drop in short interest could indicate a decrease in bearishness toward a stock. In the same period, Phillips 66 stock has risen 9.9%.
Upvote Downvote

 
How Phillips 66 Stock Could Trend pre-1Q18 Earnings Release

2018-04-18 marketrealist
In this part, we’ll forecast Phillips 66’s stock price based on its implied volatility for the 16 days leading up to its earnings release. Phillips 66 is expected to post its 1Q18 earnings on April 27, 2018. Phillips 66’s implied volatility has risen 7.0% since January 2, 2018, to 23.5%, and its stock has risen 0.8%.
Upvote Downvote

 
A Look at Phillips 66, Crack Indicators, and the Market

2018-04-18 marketrealist
Previously, we looked at Phillips 66’s (PSX) 1Q18 estimates. In this part, we’ll evaluate PSX’s stock performance before it posts its results, which expected to be released on April 27, 2018.
Upvote Downvote

 
Analysts’ Views on Phillips 66

2018-04-18 marketrealist
In this series, we’ve examined estimates for Phillips 66’s (PSX) 1Q18 results, which are expected to be released on April 27, 2018. In this part, we’ll review changes in analyst ratings for Phillips 66.
Upvote Downvote

 
The White House's Ethanol Waiver Is Not A Big Deal

2018-04-16 seekingalpha
President Donald Trump told reporters last week that his administration might remove the restrictions that prevent E15 blends from being made available year-round.
Upvote Downvote

 
PBF / PBF Energy, Inc. DEFINITIVE PROXY STATEMENT

2018-04-13 sec.gov
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
PBF / PBF Energy, Inc. DEFA14A

2018-04-13 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
PBF Stock’s Pre-Earnings Returns Put It in the Middle Order

2018-04-10 marketrealist
PBF Energy (PBF) stock’s returns put it in the fourth slot among the seven refining stocks in our survey. PBF marks the beginning of the middle order of these refining stocks. Marathon Petroleum (MPC) is also in the middle order, followed by Phillips 66 (PSX) and Valero Energy (VLO) in the bottom order. Let’s have a look at PBF Energy’s stock performance.
Upvote Downvote

 
Ranking the Pre-1Q Earnings Returns of 7 Refining Stocks

2018-04-10 marketrealist
In this series, we’ll rank seven American refining firms based on their returns in the past month. Then we’ll delve into the individual performances of these refining companies.
Upvote Downvote

 
Will Valero Meet Analysts’ Estimates in Its 1Q18 Earnings?

2018-04-10 marketrealist
Valero Energy (VLO) is expected to publish its 1Q18 results on April 26, 2018. Before we proceed with considering analysts’ 1Q18 estimates for VLO, let’s recap Valero’s 4Q17 performance compared to estimates.
Upvote Downvote

 
Venezuelan crude sales to the United States rose in March

2018-04-10 reuters
HOUSTON, April 10 (Reuters) - Venezuela’s crude sales to the United States last month rose to 454,775 barrels per day (bpd), 20 percent more than in February due to larger shipments of diluted crude, according to Thomson Reuters Trade Flows data.
Upvote Downvote

 
These Refining and Marketing Energy Stocks are Rising this Week

2018-04-06 editors.aws.marketrealist
In this part of our series, we’ll look at the top-percentage gainers from the US refining and marketing sector this week. To compile the list of top refining and marketing gainers, we’ve selected refining and marketing companies with market capitalizations greater than $100 million and average trading volume greater than 100,000 shares last week.
Upvote Downvote

 
MRC Global Braves Risks With Upstream & Midstream Growth

2018-04-06 zacks
On Apr 6, we issued an updated research report on MRC Global Inc. (MRC - Free Report) . The company is a renowned distributor of pipes, valves and fittings (PVF). These products are used across the upstream, midstream and downstream sectors of the oil and gas industry. Over the last month, this Zacks Rank #3 (Hold) stock inched up 0.4%, as against the 1.7% loss incurred by the industry.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 69318G106